Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


T cells can shift from helping to harming in atherosclerosis


LJI study brings scientists closer to designing a safe anti-atherosclerosis vaccine

High cholesterol kills. In fact, one in four Americans will die from the consequences of atherosclerosis, the buildup of plaques of fat and cholesterol in the arteries. Statins have helped reduce mortality, but millions are still at risk.

Everyone produces T cells that can recognize ApoB, the protein backbone of LDL cholesterol, better knowns as "bad" cholesterol. Image: Close-up of a T cell receptor (green) and an MHC molecule (pink), which presents a fragment of an ApoB molecule (light grey).

Credit: Ley Laboratory, La Jolla Institute for Immunology

At La Jolla Institute for Immunology (LJI) researchers are dedicated to finding a way to stop plaques from forming in the first place. In a new study, LJI scientists show that certain T lymphocytes, a type of white blood cell, that start out trying to fight the disease can end up increasing inflammation and making atherosclerosis cases even worse.

"Your immune response to self is normally anti-inflammatory, but once the disease process starts, it turns against you," says LJI Professor Klaus Ley, M.D., who led the study published July 24, 2020 in the journal Circulation.

Ley's lab specializes in studying T cells, immune cells that recognize specific peptides, or pieces of a protein. Ley's lab has found that everyone produces T cells that can recognize ApoB, the protein backbone of LDL cholesterol. LDL, sometimes called "bad" cholesterol, is important for transporting fat molecules to where they are needed in the body, but too much LDL can contribute to the plaques that narrow arteries in atherosclerosis.

Ley is hoping to someday harness the power T cells by designing a vaccine that could target LDL and prevent dangerous plaques from ever forming. In a 2018 study, Ley's team showed that an atherosclerosis vaccine could reduce plaque levels in mice.

To design a safe vaccine for human patients, Ley and his colleagues need a deep understanding of how T cells function in atherosclerosis.

For the new study, Ley worked with the lab of LJI Professor Alessandro Sette, Dr. Biol. Sci., to find the epitopes--the T cell targets--on the ApoB protein. This allowed the researchers to then build "tetramers," or molecules that they could use to find the very small population of T cells that can actually recognize those epitopes.

Using this new tracking method, Ley and his colleagues identified a group of regulatory T cells that would normally help reduce inflammation in the body. But it appears that something goes haywire in atherosclerosis that turns the function of these cells on its head. Instead of reducing inflammation, the regulatory T cells start secreting immune molecules, called cytokines, that increase inflammation and further narrow diseased arteries.

"These T cells don't cause plaques in the arteries, but they can accelerate the disease," says Ley.

The researchers saw the same phenomenon in mouse models of atherosclerosis and in human patients with coronary artery disease, caused by atherosclerosis.

"The reasons why this happens are unclear," says Ley. "We know that ApoB goes up as your cholesterol goes up, and these cells turn into pro-inflammatory cells."

The researchers found that both genetics and diet can play a role in shifting regulatory T cells from helpers to pathogenic cells. In fact, diet led to the harmful T cell shift in mice after only four weeks. This suggests a metabolic change might be behind this T cell behavior, but it is too early to know for sure.

"Obviously, we cannot have T cells switching like this after we vaccine against ApoB, so we need to better understand what is happening when the cells switch," Ley says.

Ley and his colleagues are now using a new technology (called single-cell RNA sequencing with cell-surface phenotype) to study T cells from many more patients in even more detail. They are working to understand exactly what drives the regulatory T cells to become pathogenic. "You can only protect patients if you know the mechanism," Ley says.


The study, "Pathogenic autoimmunity in atherosclerosis evolves from initially protective ApoB-reactive CD4+ 2 T-regulatory cells," was supported by the National Heart, Lung, and Blood Institute (grants HL115232, HL88093 and HL121697); the National Institutes of Health (grants AI139749 and S10 RR027366); deutsche Forschungsgemeinschaft (DFG 22 WO1994/1); a fellowship from the Berta-Ottenstein-Program for Advanced Clinician Scientists at the Faculty of Medicine, University of Freiburg; the European Research Council; and the Boehringer Ingelheim Foundation.

Additional study authors include Dennis Wolf, Nathaly Anto Michel, Akula Bala Pramod, Yanal Ghosheh, Simon Brunel, Konrad Buscher, Jacqueline Miller, Sara McArdle, Livia Baas, Kouji Kobiyama, Melanie Vassallo, Erik Ehinger, Thamotharampillai Dileepan, Amal Ali, Maximilian Schell, Zbigniew Mikulski, Daniel Sidler, Takayuki Kimura, Xia Sheng, Hauke Horstmann, Sophie Hansen, Lucia Sol Mitre, Peter Stachon, Ingo Hilgendorf, Dalia Gaddis, Catherine Hedrick, Chris A.Benedict, Bjoern Peters and Andreas Zirlik.

About La Jolla Institute for Immunology

The La Jolla Institute for Immunology is dedicated to understanding the intricacies and power of the immune system so that we may apply that knowledge to promote human health and prevent a wide range of diseases. Since its founding in 1988 as an independent, nonprofit research organization, the Institute has made numerous advances leading toward its goal: life without disease.

Media Contact

Gina Kirchweger


Gina Kirchweger | EurekAlert!

More articles from Health and Medicine:

nachricht Discovery shows promise for treating Huntington's Disease
05.08.2020 | Ecole Polytechnique Fédérale de Lausanne

nachricht Carbon monoxide improves endurance performance
05.08.2020 | Universität Bayreuth

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: ScanCut project completed: laser cutting enables more intricate plug connector designs

Scientists at the Fraunhofer Institute for Laser Technology ILT have come up with a striking new addition to contact stamping technologies in the ERDF research project ScanCut. In collaboration with industry partners from North Rhine-Westphalia, the Aachen-based team of researchers developed a hybrid manufacturing process for the laser cutting of thin-walled metal strips. This new process makes it possible to fabricate even the tiniest details of contact parts in an eco-friendly, high-precision and efficient manner.

Plug connectors are tiny and, at first glance, unremarkable – yet modern vehicles would be unable to function without them. Several thousand plug connectors...

Im Focus: New Strategy Against Osteoporosis

An international research team has found a new approach that may be able to reduce bone loss in osteoporosis and maintain bone health.

Osteoporosis is the most common age-related bone disease which affects hundreds of millions of individuals worldwide. It is estimated that one in three women...

Im Focus: AI & single-cell genomics

New software predicts cell fate

Traditional single-cell sequencing methods help to reveal insights about cellular differences and functions - but they do this with static snapshots only...

Im Focus: TU Graz Researchers synthesize nanoparticles tailored for special applications

“Core-shell” clusters pave the way for new efficient nanomaterials that make catalysts, magnetic and laser sensors or measuring devices for detecting electromagnetic radiation more efficient.

Whether in innovative high-tech materials, more powerful computer chips, pharmaceuticals or in the field of renewable energies, nanoparticles – smallest...

Im Focus: Tailored light inspired by nature

An international research team with Prof. Cornelia Denz from the Institute of Applied Physics at the University of Münster develop for the first time light fields using caustics that do not change during propagation. With the new method, the physicists cleverly exploit light structures that can be seen in rainbows or when light is transmitted through drinking glasses.

Modern applications as high resolution microsopy or micro- or nanoscale material processing require customized laser beams that do not change during...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

“Conference on Laser Polishing – LaP 2020”: The final touches for surfaces

23.07.2020 | Event News

Conference radar for cybersecurity

21.07.2020 | Event News

Contact Tracing Apps against COVID-19: German National Academy Leopoldina hosts international virtual panel discussion

07.07.2020 | Event News

Latest News

Rare Earth Elements in Norwegian Fjords?

06.08.2020 | Earth Sciences

Anode material for safe batteries with a long cycle life

06.08.2020 | Power and Electrical Engineering

Turning carbon dioxide into liquid fuel

06.08.2020 | Life Sciences

Science & Research
Overview of more VideoLinks >>>